Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Santhera renegotiates milestone payment, increases liquidity runway into 2023 pending NDA filing
4 years ago
Financing
Roche wagers $180M in quick cash on a candidate for best-in-class tumor targeting drug
4 years ago
FDA lifts hold on Legend Biotech's follow-up CAR-T targeting CD4+
4 years ago
FDA+
Trailing AstraZeneca in lupus, Bristol Myers looks to push TYK2 drug into PhIII trials
4 years ago
Sage and Biogen build out case for depression drug as it passes PhIII test in postpartum women
4 years ago
Sanofi earns breakthrough nod in hemophilia A as it continues to play catch-up with Roche's Hemlibra
4 years ago
FDA+
Research revamp: UK calls on clinical trial sponsors to shut down trials that aren't viable
4 years ago
Coronavirus
Swedish biotech crumbles in face of PhII failure of prostate cancer vaccine
4 years ago
Once again, the FDA is delaying BioMarin’s hemophilia A quest as gene therapy frets simmer
4 years ago
TG Therapeutics gets 3-month punt from FDA for standalone BLA in aftermath of Ukoniq + adcomm withdrawal
4 years ago
FDA+
Transition to new European clinical trials info system starts slowly
4 years ago
ASCO abstracts mint some early winners, but Iovance, SpringWorks get hit by massive losses
4 years ago
Keeping pressure on Amgen, Mirati draws mixed reviews on latest cut of KRAS data
4 years ago
Roche's CD20xCD3 doesn't beat Genmab at ORR, but sets bar for CR data on lymphoma drug
4 years ago
Pharma
In search of elusive NASH breakthrough, Pfizer spotlights combo approach
4 years ago
Saying goodbye to R&D chief, Flagship-backed Axcella drops PhII program as it focuses on long Covid, NASH
4 years ago
People
Coronavirus
Planning ahead for crowded ulcerative colitis market, Pfizer spells out PhIII data on $6.7B Arena drug
4 years ago
Pfizer spinout SpringWorks will ship its first drug to the FDA before year’s end with PhIII win
4 years ago
A new era of treatment: How biomarkers are changing the way we think about cancer
4 years ago
In Focus
Blaming Covid disruption, supply shortages, microcap biotech hits the brakes on cell therapy trial
4 years ago
Cell/Gene Tx
Lilly's mirikizumab, once a contender for psoriasis, bolsters case for UC indication in maintenance trial data readout
4 years ago
Pharma
Idorsia claims PhIII win for hypertension drug at center of $230M J&J deal
4 years ago
'Xenotransplantation is coming': New NEJM paper gives detailed look into 2 pig-to-human kidney transplant cases
4 years ago
One trial down, one to go as Concert Pharmaceuticals tunes up PhIII win for alopecia drug
4 years ago
First page
Previous page
134
135
136
137
138
139
140
Next page
Last page